Who are THR-100's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b2 Pfizer-BioNTech/Comirnaty, Combination BNT162b2 and BNT162b2 OMI, Moderna mRNA-1273 COVID-19 vaccine, BNT162b7 Monovalent (OMI BA.4/BA.5), Famtozinameran 5 to 11 Years of age, BNT162b2 Bivalent (WT/OMI BA.1).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thr-100.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

THR-100 — Competitive Intelligence Brief

THR-100 (THR-100) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COVID-19 vaccine. Area: Infectious disease.

phase 3 COVID-19 vaccine SARS-CoV-2 spike protein Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

THR-100 (THR-100) — Bharat Biotech International Limited. THR-100 is a recombinant human monoclonal antibody that targets the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
THR-100 TARGET	THR-100	Bharat Biotech International Limited	phase 3	COVID-19 vaccine	SARS-CoV-2 spike protein
BNT162b2 Pfizer-BioNTech/Comirnaty	BNT162b2 Pfizer-BioNTech/Comirnaty	KK Women's and Children's Hospital	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Combination BNT162b2 and BNT162b2 OMI	combination-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Moderna mRNA-1273 COVID-19 vaccine	Moderna mRNA-1273 COVID-19 vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
BNT162b7 Monovalent (OMI BA.4/BA.5)	bnt162b7-monovalent-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Famtozinameran 5 to 11 Years of age	famtozinameran-5-to-11-years-of-age	Pfizer	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (COVID-19 vaccine class)

Bharat Biotech International Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). THR-100 — Competitive Intelligence Brief. https://druglandscape.com/ci/thr-100. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab